⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048797 | 0.80 | — | — | |
| Tert-Butyl Formate SCHEMBL27970682 | 0.80 | TDP1 (0.43) | — | |
| SCHEMBL4588217 | 0.78 | — | — | |
| SCHEMBL348086 | 0.77 | MAPT (0.31) | — | |
| SCHEMBL2000341 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL17361360 | 0.76 | — | — | |
| SCHEMBL7079017 | 0.74 | — | — | |
| SCHEMBL869315 | 0.74 | — | — | |
| SCHEMBL7812654 | 0.74 | — | — | |
| SCHEMBL244009 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241562-A | Synthesis method of pyrazole tricyclic compound | 安徽大学 | 2025-01-03 | — | — | CN | claimed |
| EP-0293220-B1 | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing | ORTHO PHARMA CORP (US) | 1994-08-31 | — | — | EP | claimed |
| EP-0293220-A2 | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-11-30 | — | — | EP | claimed |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12534487-B2 | Compounds for use as iron(III) MRI contrast agents | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-01-27 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| CN-119241562-A | Synthesis method of pyrazole tricyclic compound | 安徽大学 | 2025-01-03 | — | — | CN | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240228524-A1 | IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS | NATIONAL SCIENCE FOUNDATION | 2024-07-11 | — | — | US | disclosed |
| EP-3551625-B1 | HETEROCYCLIC INHIBITORS OF MCT4 | VETTORE LLC (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-117729943-A | Iron (III) macrocyclic complexes with mixed hydroxyl side groups as MRI contrast agents | 纽约州立大学研究基金会 | 2024-03-19 | — | — | CN | disclosed |
| US-4151288-A | ANTHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-04-24 | — | — | US | disclosed |
| US-4137234-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4137237-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4070475-A | THIOALKYL-, AMINOALKYL-, AND OXYALKYL- SUBSTITUTED GUANIDINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-01-24 | — | — | US | disclosed |
| US-4024271-A | INHIBITORS OF HISTAMINE ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-17 | — | — | US | disclosed |
| US-4022797-A | PHARMACEUTICALS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-10 | — | — | US | disclosed |
| US-4018931-A | INHIBITION OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-04-19 | — | — | US | disclosed |
| US-3950333-A | HISTAMINE INHIBITORS, OXYALKYL, THIOALKYL, AMINOALKYL DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
| US-3950353-A | HISTAMINE INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |